Quarterly report pursuant to Section 13 or 15(d)

Note 15 - Segments - Segment Information (Details)

v3.21.2
Note 15 - Segments - Segment Information (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Revenue from contract with customer $ 13,000   $ 9,000   $ 36,000 $ 24,000  
Grant and other revenue 247,983   262,181   349,234 403,232  
Revenues, Total 261,046   271,101   384,783 427,373  
Research and development expenses 1,498,056   1,281,779   2,720,810 2,281,048  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 1,412,752   1,310,335   3,625,749 3,121,246  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 19,858   19,256   37,606 36,099  
Loss from operations [3] (2,669,620)   (2,340,626)   (5,999,382) (5,011,986)  
Other expense (4) [4] (4,420)            
Net loss (2,674,040) $ (2,966,892) (2,325,619) $ (2,673,608) (5,640,932) (4,999,227)  
Total assets, net of depreciation and amortization 11,281,310       11,281,310   $ 7,758,018
Capital expenditures 2,707   1,947   2,707 8,406  
Cost of revenue 0   357   0 966  
Other income (4) (4,420)   15,007 [4]   358,450 [4] 12,759 [4]  
UNITED STATES              
Total assets, net of depreciation and amortization 11,080,979   6,606,683   11,080,979 6,606,683  
Non-US [Member]              
Total assets, net of depreciation and amortization 200,331       200,331    
License [Member]              
Revenue from contract with customer 13,063   0   35,549 0  
Royalty [Member]              
Revenue from contract with customer 0   8,920   0 24,141  
Diagnostics Segment [Member]              
Grant and other revenue 247,983   215,458   349,234 274,374  
Revenues, Total 261,046   224,378   384,783 298,515  
Research and development expenses 1,358,123   1,193,151   2,452,513 2,150,777  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 0   0   0 0  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 6,041   0   12,081 0  
Loss from operations [3] (1,103,118)   (969,130)   (2,079,811) (1,853,228)  
Other expense (4) [4] 0            
Net loss (1,103,118)   (969,130)   (2,079,811) (1,853,228)  
Capital expenditures 0   0   0 0  
Cost of revenue     357     966  
Other income (4) [4]     0   0 0  
Diagnostics Segment [Member] | UNITED STATES              
Total assets, net of depreciation and amortization 269,464   107,185   269,464 107,185  
Diagnostics Segment [Member] | Non-US [Member]              
Total assets, net of depreciation and amortization 199,741       199,741    
Diagnostics Segment [Member] | License [Member]              
Revenue from contract with customer 13,063       35,549    
Diagnostics Segment [Member] | Royalty [Member]              
Revenue from contract with customer     8,920     24,141  
Therapeutics Segment [Member]              
Grant and other revenue 0   46,723   0 128,858  
Revenues, Total 0   46,723   0 128,858  
Research and development expenses 139,933   88,628   268,297 130,271  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 873   972   2,879 (550)  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 0   0   0 0  
Loss from operations [3] (140,806)   (42,877)   (271,176) (863)  
Other expense (4) [4] 0            
Net loss (140,806)   (42,877)   (271,176) (863)  
Capital expenditures 0   0   0 0  
Cost of revenue     0     0  
Other income (4) [4]     0   0 0  
Therapeutics Segment [Member] | UNITED STATES              
Total assets, net of depreciation and amortization 0   36,483   0 36,483  
Therapeutics Segment [Member] | Non-US [Member]              
Total assets, net of depreciation and amortization 0       0    
Therapeutics Segment [Member] | License [Member]              
Revenue from contract with customer 0       0    
Therapeutics Segment [Member] | Royalty [Member]              
Revenue from contract with customer     0     0  
Corporate Segment [Member]              
Grant and other revenue 0   0   0 0  
Revenues, Total 0   0   0 0  
Research and development expenses 0   0   0 0  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 1,411,879   1,309,363   3,622,870 3,121,796  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 13,817   19,256   25,525 36,099  
Loss from operations [3] (1,425,696)   (1,328,619)   (3,648,395) (3,157,895)  
Other expense (4) [4] (4,420)            
Net loss (1,430,116)   (1,313,612)   (3,289,945) (3,145,136)  
Capital expenditures 2,707   1,947   2,707 8,406  
Cost of revenue     0     0  
Other income (4) [4]     15,007   358,450 12,759  
Corporate Segment [Member] | UNITED STATES              
Total assets, net of depreciation and amortization 10,811,515   6,463,015   10,811,515 6,463,015  
Corporate Segment [Member] | Non-US [Member]              
Total assets, net of depreciation and amortization 590       590    
Corporate Segment [Member] | License [Member]              
Revenue from contract with customer $ 0       $ 0    
Corporate Segment [Member] | Royalty [Member]              
Revenue from contract with customer     $ 0     $ 0  
[1] General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.
[2] Depreciation and amortization are reflected in selling, general and administrative expenses ($19,858 and $19,256 for the three-month periods ended June 30, 2021 and 2020, and $37,606 and $36,099 for the six-month periods ended June 30, 2021 and 2020, respectively).
[3] Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.
[4] Amounts consist primarily of interest income and interest expense, which are not currently allocated to our individual reportable segments.